Initiation of dosing in our Phase 1b clinical trial represents an important step in the clinical development of GT-02287 and in Gain’s mission to deliver a disease-modifying therapy to people with ...
Gain Therapeutics (GANX) announced the dosing of the first participant with Parkinson’s disease in its Phase 1b clinical trial of GT-02287, the ...
Interim Analysis Expected End of 2Q 2025 BETHESDA, MD / ACCESS Newswire / March 14, 2025 / Gain Therapeutics, Inc. (Nasdaq:GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company lead ...
ScienceAlert on MSN2d
World First: Physicists Create a Supersolid Out of LightAt first, the photons settle into a state with zero momentum, but as this state 'fills up', pairs of photons begin to spill ...
Abcuro, Inc., a clinical-stage biotechnology company developing therapies for the treatment of autoimmune diseases and cancer through precise modulation of cytotoxic T cells, today announced that the ...
Hudson Therapeutics, the U.S. subsidiary of Shaperon, announced today that Shaperon will commence the Phase 2b Part 2 of its ...
A team of Italian scientists has successfully made light behave like a supersolid for the first time. Published in Nature ...
EOMs are commonly used in applications that require q-switching such as research laser systems, military lasers, and medical ...
National MS Education and Awareness Month is celebrated each year in the US in March, after having been launched in 2003 by ...
Tonix Pharmaceuticals (NASDAQ: TNXP) is working to improve organ transplant success rates with TNX-1500, a third-generation CD40L blocker designed to ...
Pathmaker's MyoRegulator is designed to ease hyperexcitability and delivers an electrical current to the spinal cord and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback